Piper Sandler raised the firm’s price target on Ironwood to $21 from $20 and keeps an Overweight rating on the shares following the quarterly results. Total Linzess sales for 2023 grew by 7% over 2022, with management citing overall demand growth of 10%, but this is really an apraglutide story now, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IRWD: